Workflow
易瑞生物:7306万欧元海外合作落地,强强联合打开全球乳品检测市场

Core Viewpoint - The collaboration between EasyBio and Chr. Hansen marks a significant step in the company's internationalization strategy, with a sales target of €73.06 million (over 600 million RMB) from 2025 to 2029, which is expected to positively impact the company's future performance and market presence [1][2][6]. Group 1: Contract Details - EasyBio has signed a cooperation agreement with Chr. Hansen, setting a total sales target of €73.06 million for the period from 2025 to 2029, with the first year's target accounting for approximately 42.18% of the company's 2024 revenue [1][2]. - The sales targets are structured to grow by more than 10% in the first year and 12% in subsequent years, with annual targets increasing from approximately 95 million RMB in 2025 to nearly 150 million RMB in 2029 [2]. - The contract allows Chr. Hansen exclusive rights to sell and promote EasyBio's products globally, excluding specific countries, covering various testing products related to food safety [2][4]. Group 2: Strategic Importance - The partnership is a major breakthrough in EasyBio's internationalization strategy, which has been a key driver of the company's performance since 2023 [2]. - The collaboration will utilize a dual-brand approach, enhancing EasyBio's market penetration in the global dairy product sector while leveraging Chr. Hansen's brand influence [4]. - EasyBio aims to expand its market reach and product offerings beyond dairy, exploring opportunities in various sectors such as food, agriculture, and pharmaceuticals, supported by Chr. Hansen's and Novonesis's expertise [5]. Group 3: Market Impact - The collaboration is expected to enhance EasyBio's core competitiveness and market influence, contributing to sustainable business growth [6]. - EasyBio's international sales have shown significant growth, with overseas revenue increasing by 15.92% in 2024, reaching approximately 93.33 million RMB, and the proportion of overseas revenue rising from 31.68% in 2023 to 41.62% in 2024 [5].